The Impact of Glycemic Control on Rheumatoid Arthritis Disease Activity on Diabetic Patients
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Rheumatoid Arthritis (RA, Diabetes Mellitus. Basic parameters: 18 years — 65 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Egypt
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
The Impact of Glycemic Control on Rheumatoid Arthritis Disease Activity in Diabetic Patients
Overview
The incidence of DM is unclear in RA but most prior data suggest that DM or insulin resistance in RA has risen because of activation of the immune system and/or RA therapy . Besides, RA causes joints to become stiff, swollen, and agonizing. As a result, the patient may not want to exercise or move. One study found that 42% of people with RA are not physically active. the aim of this study is To evaluate the glycemic status among RA patients with Type 2 diabetes and its association with disease activity.
Detailed description
Taking the potential link between DM and RA into consideration, detection and control of DM will significantly increase prolonged prognosis and therefore decrease the economic burden of RA patients and death rate. The aim of this research is to examine diabetic RA's glycemic status and to assess the relationship between RA and DM's clinical characteristics as well as the therapy response in RA patients with diagnosed DM. Keeping an eye on glycemic control in RA patients could prevent metabolic and cardiovascular comorbidities in those susceptible patients.
Primary outcome measures
- Fasting blood glucose [Time frame: baseline]
Eligibility criteria
Inclusion criteria
- type 2 diabetic patients
- rheumatoid arthritis patients
Exclusion criteria
- gestional diabetes
- type 1 diabetic patients
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Case-only
Study locations
Egypt · 1 center
- Assiut university — Asyut
Identifiers
NCT: NCT06691997 · DM and Rheumatoid Arthritis